Microcap Ledger Creative Medical Technology Holdings, Inc. $CELZ
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Phoenix, AZ
- Fiscal year end
- December 31
- Shares outstanding
- 6,592,557 [10-Q 2026-08-07]
What the company doesAI summary of filing
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company developing regenerative therapies using stem cells and reprogrammed immune cells. The company's lead programs in clinical trials include CELZ-201 for Type 1 Diabetes treatment (Phase 1/2a FDA-approved) and AlloStemSpine (CELZ-201 ADAPT) for chronic lower back pain (Phase 1/2a FDA-approved with enrollment completed as of December 2025). The company also markets autologous stem cell procedures including StemSpine for lower back pain and CaverStem for erectile dysfunction, which generated minimal revenues in 2023 and 2024. Additional programs in development include ImmCelz (CELZ-100) for immunotherapy indications, OvaStem for premature ovarian failure, and iPScelz derived from induced pluripotent stem cells developed with partner Greenstone Biosciences. [10-K 2026-03-20]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$2.92M | −$2.80M | $8.71M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $6.0K | −$6.00M | −$5.86M | $7.21M | [10-K 2026-03-20] |
| FY ended Dec 2024 | $11.0K | −$5.49M | −$5.30M | $5.94M | [10-K 2026-03-20] |
- Quarterly cash burn
- −$1.40M
- Cash runway Estimate
- ~18.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-22 | 1,748,428 | [10-K 2025-03-14] |
| 2025-04-15 | 2,585,897 | [10-K/A 2025-04-25] |
| 2025-05-09 | 2,585,532 | [10-Q 2025-05-09] |
| 2025-08-01 | 2,580,532 | [10-Q 2025-08-08] |
| 2025-11-01 | 2,580,532 | [10-Q 2025-11-07] |
| 2026-03-20 | 3,696,668 | [10-K/A 2026-04-24] |
| 2026-05-01 | 3,696,668 | [10-Q 2026-05-08] |
| 2026-08-07 | 6,592,557 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2026-07-24; declared effective 2026-07-31 [S-3 2026-07-24]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-04-11. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-04-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-11] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-24 | Warbington Timothy | grant | 1,000,000 | — | [4 2026-09-25] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-01 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-09-25 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-08-31 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-03 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-24 | S-3 | Registration statement |
| 2026-07-14 | DEF 14A | Proxy statement |
| 2026-07-02 | 8-K | Material agreement entered; Unregistered sale of equity; Director or officer change |
| 2026-07-01 | PRE 14A | Proxy statement |
| 2026-06-26 | S-1/A | Registration statement |
| 2026-06-25 | S-1 | Registration statement |
| 2026-05-08 | 10-Q | Quarterly report |
Alerts for $CELZ
Email me when Creative Medical Technology Holdings, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.